The Best Ways to Achieve Remission in JIA

There’s no cure for juvenile idiopathic arthritis, but early, aggressive treatment could lead to long-term remission.

By Stephanie Watson 

Without a cure for juvenile idiopathic arthritis (JIA), doctors aim to put kids into remission — or long periods of little or no disease activity and symptoms. Research finds that treating the disease early and aggressively offers children the best odds of slowing disease progression and achieving long-term symptom relief.

Benefits of Early, Aggressive Treatment

A few studies have shown that starting aggressive therapy early in the course of the disease provides the best results for kids with JIA.

In one key study, researchers compared two aggressive treatments: methotrexate in combination with a biologic drug and a steroid or methotrexate alone. They found that both treatments helped children achieve clinical inactive disease (CID)—meaning they had no signs of active inflammation. Two-thirds of the children achieved CID within 12 months on treatment. For each month earlier doctors started treatment, the proportion of kids who achieved inactive disease increased 1.3-fold.

“I think there are strong data showing that early, aggressive therapy really helps these kids, and that it’s the way to go,” says Susan Shenoi, MBBS, MS, pediatric rheumatologist at Seattle Children’s Hospital and assistant professor of pediatric rheumatology at the University of Washington.

When children with polyarticular (multiple joint) JIA achieve CID quickly, it also reduces their risk for a flare in the future, according to a 2018 study in Arthritis & Rheumatology.

 “Not only does early aggressive therapy have an impact on getting them to clinically inactive disease, but it also has an impact down the road,” says Dan Lovell, MD, MPH, lead author of that study and Joseph E. Levinson Chair of Pediatric Rheumatology at Cincinnati Children’s Medical Center.

Treatment strategy varies from child to child based on the severity of their disease, the number of joints involved, the family’s personal preference and which medications their insurance will cover. The most aggressive approach for JIA when it affects four or more joints combines methotrexate with a biologic and prednisone, but not every child will need all three drugs. In those with milder disease and fewer involved joints, methotrexate alone may be enough.

The Window of Opportunity

Some researchers who study JIA use the term “window of opportunity.” It’s the idea that there is a period of time in which the disease responds best to treatment. Kids who take medication during this time are most likely to achieve long-term remission and avoid permanent joint damage.

“There seems to be a trend where, if you treat kids early on with an effective medication, they have better outcomes and achieve inactive disease,” Dr. Shenoi says. Often the term “window of opportunity” is used specifically for kids with systemic JIA—one of the most severe forms of the disease.

For these children, the most effective therapy is with interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors. “The IL-1 and IL-6 inhibitors have revolutionized the way we treat systemic JIA,” says Dr. Shenoi. “Studies show that if you start kids on an IL-1 inhibitor like anakinra (Kineret) early on, there seems to be a dramatic change in their outcome, with several of them achieving inactive disease or remission.”

Treat to Target

Treat to target is another JIA treatment that has been used for many years in adults with rheumatoid arthritis and other chronic conditions like high blood pressure and diabetes.

“In treat to target, patients and physicians work together to come to an agreement on what the outcome or target [usually remission or low disease activity] needs to be, and they keep adapting the therapy to make sure that the target is achieved,” Dr. Shenoi says.

The chosen target varies, but the most common one for JIA is CID or remission. At each visit, the parents, doctor and patient evaluate the progress and decide whether to stay with the same treatment or make a change. 

New treatment guidelines published April 11, 2018 in the Annals of the Rheumatic Diseases recommend the use of treat to target in children with JIA, yet few doctors have adopted this approach.

“One reason is that it’s time consuming, because you have to discuss with the family about what the target is, collect the data and do the assessments at future visits,” says Dr. Lovell, who was a member of the task force that developed the new guidelines.

However, the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is testing various treat-to-target interventions to streamline the process.

Researchers at Children’s Hospital of Philadelphia tried the treat-to-target approach in 112 patients with polyarticular JIA and 358 patients with other subtypes of the disease. After a year, disease activity improved by 36 percent, and the proportion of patients in remission increased from 31 to 49 percent, according to results presented at the 2017 American College of Rheumatology annual meeting.

Remission On and Off Medications

If remission is achieved, there’s a risk is that the disease will flare again.

“We know that for polyarticular JIA, if children get to clinical inactive disease and stay there for at least six months, and then stop biologic therapy, 50 percent will flare and 50 percent will continue to do well for a period of time,” Dr. Lovell says. Exactly which children will flare off treatment is difficult to determine.

 “We don’t have enough data to predict when, and if, a flare might happen,” says Nancy Pan, MD, a pediatric rheumatologist at the Hospital for Special Surgery in New York. She adds that flares can happen shortly after kids stop treatment, or months or years later.

Researchers are looking for biomarkers that might help them predict which children can stop treatment, and which ones should continue their medications because they’re at a high risk for flaring.

"When children stop treatment and flare up, even if they go back on their original therapy they won’t necessarily achieve remission again,” Dr. Lovell says. Doctors and families must weigh the risk of medication side effects against the chance that the disease will come back.

Positive Outlook

The outlook for kids with JIA has improved dramatically in recent years. Biologic drugs and other new treatments are helping kids stay mobile and avoid long-term joint damage. Early intervention with effective medication is the most critical component to achieving remission in kids with JIA—but it’s not the only treatment strategy. Practicing healthy lifestyle habits, like eating a nutritious diet and getting regular exercise is essential for these kids. “Physical therapy is also important for a lot of patients to maintain their range of motion,” Dr. Pan says.

 

 

Diagnosed With Juvenile Arthritis?

Get the latest news and tips about living with Juvenile Arthritis in the Living Your Yes! e-newsletter.

 
I Want to Contribute
I Need Help
  • Donate

    Donate

    Every gift to the Arthritis Foundation will help people with arthritis across the U.S. live their best life.

  • Volunteer

    Volunteer

    Join us and become a Champion of Yes. There are many volunteer opportunities available.

  • Live Yes! INSIGHTS

    Live Yes! INSIGHTS

    Take part to be among those changing lives today and changing the future of arthritis.

  • Partner

    Partner

    Proud Partners of the Arthritis Foundation make an annual commitment to directly support the Foundation’s mission.

Donate


Make a Donation

Help millions of people live with less pain and fund groundbreaking research to discover a cure for this devastating disease. Please, make your urgently-needed donation to the Arthritis Foundation now!

Become a Member

Become an Arthritis Foundation member today for just $20. You'll receive a year's worth of Arthritis Today magazine, access to helpful tools, resources, and more.

Make a Honor or Memorial Gift

Honor a loved one with a meaningful donation to the Arthritis Foundation. We'll send a handwritten card to the honoree or their family notifying them of your thoughtful gift.

Volunteer


Volunteer Opportunities

The Arthritis Foundation is focused on finding a cure and championing the fight against arthritis with life-changing information, advocacy, science and community. We can only achieve these goals with your help. Strong, outspoken and engaged volunteers will help us conquer arthritis. By getting involved, you become a leader in our organization and help make a difference in the lives of millions. Join us and become a Champion of Yes.


More About Volunteering

Live Yes! INSIGHTS


Give Just 10 Minutes.

Tell us what matters most to you. Change the future of arthritis.

By taking part in the Live Yes! INSIGHTS assessment, you’ll be among those changing lives today and changing the future of arthritis, for yourself and for 54 million others. And all it takes is just 10 minutes.

Your shared experiences will help:

- Lead to more effective treatments and outcomes
- Develop programs to meet the needs of you and your community
- Shape a powerful agenda that fights for you

Now is the time to make your voice count, for yourself and the entire arthritis community. 

Currently this program is for the adult arthritis community.  Since the needs of the juvenile arthritis (JA) community are unique, we are currently working with experts to develop a customized experience for JA families. 


How are you changing the future?

By sharing your experience, you’re showing decision-makers the realities of living with arthritis, paving the way for change. You’re helping break down barriers to care, inform research and create resources that make a difference in people’s lives, including your own.

Get Started

 

Partner


Meet Our Partners

As a partner, you will help the Arthritis Foundation provide life-changing resources, science, advocacy and community connections for people with arthritis, the nations leading cause of disability. Join us today and help lead the way as a Champion of Yes.

Trailblazer

Our Trailblazers are committed partners ready to lead the way, take action and fight for everyday victories. They contribute $2,000,000 to $2,749,000

Visionary

Our Visionary partners help us plan for a future that includes a cure for arthritis. These inspired and inventive champions have contributed $1,500,00 to $1,999,999.

Pioneer

Our Pioneers are always ready to explore and find new weapons in the fight against arthritis. They contribute $1,000,000 to $1,499,999.

Pacesetter

Our Pacesetters ensure that we can chart the course for a cure for those who live with arthritis. They contribute $500,000 to $999,000.

Signature

Our Signature partners make their mark by helping us identify new and meaningful resources for people with arthritis. They contribute $250,000 to $499,999.

Supporting

Our Supporting partners are active champions who provide encouragement and assistance to the arthritis community. They contribute $100,000 to $249,999.

More About Partnerships